About DoseVue

Get to know our people and story

DoseVue History

DoseVue was founded in 2013 as the first spin-off of the Belgian Nuclear Research Center (SCK•CEN), an internationally renowned player in the field of radiation protection and dosimetry research. Together with academic and industry partners (including SIT and Eckert Ziegler), we are continually expanding our product portfolio of in-vivo dosimetry solutions. With the dedicated support of our investors Innovation Fund and LRM, DoseVue is led by an experienced management team and board of directors.

Board of Directors

Staf Van Reet

Chairman of the board, Senior Executive

Dr. Staf Van Reet is the Managing Director of VIZIPhar Biosciences. Staf was formerly active as Managing Director of Janssen Pharmaceutica, Head of R&D of the Janssen Group and a member of the Group Operating Committee of the pharmaceutical sector of Johnson & Johnson. From 2000 – 2004, Staf was Vice President of the Johnson & Johnson Development Corporation, the venture capital arm of Johnson & Johnson. He was a co-founder and Chairman of the Board of Directors of Movetis until the company was acquired by Shire Holdings in 2010. Currently, Staf is Chairman of the Board of Directors of Thrombogenics, Actogenix and the Flemish Institute for Biotechnology (VIB) and a Director of Biocartis and Therasolve. Staf obtained his Master and PhD in Bio-engineering Sciences from KU Leuven.

Dries Evens

Investment Manager, LRM

Christian Legrain

Vice President, European Nuclear Society

Hildegarde Vandenhove

Director Environment Health and Safety, Belgian Nuclear Research Centre (SCK-CEN)

André Ostachkov

Principal, The Innovation Fund

Partners

Discover the future of
dosimetry with DoseVue

Get in touch